These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Side Effects and Efficacy of Immunotherapy. Fiala O; Šorejs O; Šustr J; Fínek J Klin Onkol; 2020; 33(1):8-10. PubMed ID: 32075381 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. Chen YM J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088 [TBL] [Abstract][Full Text] [Related]
15. A decade of immune-checkpoint inhibitors in cancer therapy. Robert C Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879 [TBL] [Abstract][Full Text] [Related]
16. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma? Dhariwal R; Pindoria N; Dasgupta P; Khan MS BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606 [No Abstract] [Full Text] [Related]
17. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093 [TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy for renal cell carcinoma - current status]. Grimm MO; Foller S Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324 [TBL] [Abstract][Full Text] [Related]
19. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. Schmidinger M Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250 [TBL] [Abstract][Full Text] [Related]